Lantern Pharma Inc. (LTRN)
NASDAQ: LTRN · Real-Time Price · USD
2.240
-0.220 (-8.94%)
At close: Apr 28, 2026, 4:00 PM EDT
2.388
+0.148 (6.60%)
After-hours: Apr 28, 2026, 6:38 PM EDT

Lantern Pharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2018
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2018
Selling, General & Admin
6.466.095.985.835.02
Upgrade
Research & Development
11.5116.1311.898.66.57
Upgrade
Operating Expenses
17.9822.2217.8814.4311.59
Upgrade
Operating Income
-17.98-22.22-17.88-14.43-11.59
Upgrade
Interest & Investment Income
0.440.740.770.20.07
Upgrade
Other Non Operating Income (Expenses)
0.380.541.15-0.030.05
Upgrade
EBT Excluding Unusual Items
-17.16-20.94-15.96-14.26-11.47
Upgrade
Gain (Loss) on Sale of Investments
0.040.16---
Upgrade
Other Unusual Items
-----0.89
Upgrade
Pretax Income
-17.12-20.78-15.96-14.26-12.36
Upgrade
Net Income
-17.12-20.78-15.96-14.26-12.36
Upgrade
Net Income to Common
-17.12-20.78-15.96-14.26-12.36
Upgrade
Shares Outstanding (Basic)
1111111111
Upgrade
Shares Outstanding (Diluted)
1111111111
Upgrade
Shares Change (YoY)
1.26%-0.74%-0.08%-0.50%153.31%
Upgrade
EPS (Basic)
-1.57-1.93-1.47-1.31-1.13
Upgrade
EPS (Diluted)
-1.57-1.93-1.47-1.31-1.13
Upgrade
Free Cash Flow
-15.68-17.83-14.37-12.8-10.61
Upgrade
Free Cash Flow Per Share
-1.44-1.66-1.32-1.18-0.97
Upgrade
EBITDA
-17.96-22.2-17.86-14.42-11.58
Upgrade
D&A For EBITDA
0.020.020.010.010.01
Upgrade
EBIT
-17.98-22.22-17.88-14.43-11.59
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.